Titre :

Allogeneic hematopoietic cell transplantation for Hodgkin''s disease, mantle cell lymphoma and other rare entities: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Auteur(s) :

Gauthier, Jordan [Auteur]
Chantepie, Sylvain [Auteur]
Bouabdallah, Krimo [Auteur]
Jost, Edgar [Auteur]
Nguyen, Stephanie [Auteur]
Gac, Anne-Claire [Auteur]
Damaj, Gandhi [Auteur]
Dulery, Remy [Auteur]
Michallet, Mauricette [Auteur]
Delage, Jeremy [Auteur]
Lewalle, Philippe [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Salles, Gilles [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Cornillon, Jerome [Auteur]

Titre de la revue :

Bulletin du cancer

Nom court de la revue :

Bull. Cancer

Numéro :

104

Pagination :

S112-S120

Date de publication :

2017

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic haematopoietic cell transplantation is a potentially ...
Lire la suite >Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic haematopoietic cell transplantation is a potentially curative option, in particular in the case of relapse after autologous stem cell transplantation. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic haematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), we performed a comprehensive review of the literature published in the last 10 years and established guidelines to clarify the indications and transplant modalities in this setting. This manuscript specifically reports on our conclusions regarding Hodgkin's lymphoma as well as rarer entities, such as T cell lymphomas.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille
Inserm

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Équipe(s) de recherche :

Innovation/évaluation des médicaments injectables

Date de dépôt :

2019-02-26T17:07:02Z